{"id": 7, "relation": 0, "prompt": "Antacids: Absorption of a single dose of <e1> Myfortic </e1> was decreased when administered to 12 stable renal transplant patients also taking magnesium-aluminum containing <e2> antacids </e2> (30 mL): the mean Cmax and AUC(0-t) values for MPA were 25% and 37% lower, respectively, than when Myfortic was administered alone under fasting conditions.\n\n###\n\n", "completion": " false"}
{"id": 5, "relation": 1, "prompt": "Antacids: Absorption of a single dose of <e1> Myfortic </e1> was decreased when administered to 12 stable renal transplant patients also taking <e2> magnesium </e2> -aluminum containing antacids (30 mL): the mean Cmax and AUC(0-t) values for MPA were 25% and 37% lower, respectively, than when Myfortic was administered alone under fasting conditions.\n\n###\n\n", "completion": " true"}
{"id": 13, "relation": 0, "prompt": "Antacids: Absorption of a single dose of Myfortic was decreased when administered to 12 stable renal transplant patients also taking magnesium- <e1> aluminum </e1> containing antacids (30 mL): the mean Cmax and AUC(0-t) values for MPA were 25% and 37% lower, respectively, than when <e2> Myfortic </e2> was administered alone under fasting conditions.\n\n###\n\n", "completion": " false"}
{"id": 89, "relation": 1, "prompt": "The addition of <e1> aspirin </e1> to <e2> Streptokinase </e2> causes a minimal increase in the risk of minor bleeding (3.9% vs. 3.1%), but does not appear to increase the incidence of major bleeding (see\n\n###\n\n", "completion": " true"}
{"id": 14, "relation": 0, "prompt": "Antacids: Absorption of a single dose of Myfortic was decreased when administered to 12 stable renal transplant patients also taking magnesium-aluminum containing <e1> antacids </e1> (30 mL): the mean Cmax and AUC(0-t) values for MPA were 25% and 37% lower, respectively, than when <e2> Myfortic </e2> was administered alone under fasting conditions.\n\n###\n\n", "completion": " false"}
{"id": 104, "relation": 1, "prompt": "Although specific drug or food interactions with mifepristone have not been studied, on the basis of this drug s metabolism by CYP 3A4, it is possible that <e1> ketoconazole </e1> , itraconazole, erythromycin, and grapefruit juice may inhibit its metabolism (increasing serum levels of <e2> mifepristone </e2> ).\n\n###\n\n", "completion": " true"}
{"id": 15, "relation": 0, "prompt": "It is recommended that <e1> Myfortic </e1> and <e2> antacids </e2> not be administered simultaneously.\n\n###\n\n", "completion": " false"}
{"id": 116, "relation": 1, "prompt": "John s Wort, and certain anticonvulsants ( <e1> phenytoin </e1> , phenobarbital, carbamazepine) may induce <e2> mifepristone </e2> metabolism (lowering serum levels of mifepristone).\n\n###\n\n", "completion": " true"}
{"id": 19, "relation": 0, "prompt": "<e1> Acyclovir </e1> / <e2> Ganciclovir </e2> : may be taken with Myfortic;\n\n###\n\n", "completion": " false"}
{"id": 151, "relation": 1, "prompt": "The following agents may increase certain actions or side effects of <e1> anticholinergic drugs </e1> : amantadine, antiarrhythmic agents of class I (e.g., <e2> quinidine </e2> ), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.\n\n###\n\n", "completion": " true"}
{"id": 21, "relation": 0, "prompt": "Acyclovir/ <e1> Ganciclovir </e1> : may be taken with <e2> Myfortic </e2> ;\n\n###\n\n", "completion": " false"}
{"id": 162, "relation": 1, "prompt": "The following agents may increase certain actions or side effects of <e1> anticholinergic drugs </e1> : amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, <e2> tricyclic antidepressants </e2> , and other drugs having anticholinergic activity.\n\n###\n\n", "completion": " true"}
{"id": 23, "relation": 0, "prompt": "Both <e1> acyclovir </e1> /ganciclovir and <e2> MPAG </e2> concentrations are increased in the presence of renal impairment, their coexistence may compete for tubular secretion and further increase in the concentrations of the two.\n\n###\n\n", "completion": " false"}
{"id": 265, "relation": 1, "prompt": "Impaired renal function has been described in bone marrow transplant patients who were conditioned with high-dose intravenous <e1> melphalan </e1> and who subsequently received <e2> cyclosporin </e2> to prevent graft-versus-host disease\n\n###\n\n", "completion": " true"}
{"id": 30, "relation": 0, "prompt": "<e1> Azathioprine </e1> /Mycophenolate Mofetil: Given that azathioprine and mycophenolate mofetil inhibit purine metabolism, it is recommended that Myfortic not be administered concomitantly with azathioprine or <e2> mycophenolate mofetil </e2> .\n\n###\n\n", "completion": " false"}
{"id": 272, "relation": 1, "prompt": "Antihypertensive effects of <e1> guanethidine </e1> and related compounds may be counteracted when <e2> phenothiazines </e2> are used concomitantly.\n\n###\n\n", "completion": " true"}
{"id": 34, "relation": 0, "prompt": "Azathioprine/ <e1> Mycophenolate Mofetil </e1> : Given that azathioprine and mycophenolate mofetil inhibit purine metabolism, it is recommended that Myfortic not be administered concomitantly with <e2> azathioprine </e2> or mycophenolate mofetil.\n\n###\n\n", "completion": " false"}
{"id": 274, "relation": 1, "prompt": "Concomitant administration of <e1> vancomycin </e1> and <e2> anesthetic agents </e2> has been associated with erythema and histamine-like flushing and anaphylactoid reactions.\n\n###\n\n", "completion": " true"}
{"id": 35, "relation": 0, "prompt": "Azathioprine/ <e1> Mycophenolate Mofetil </e1> : Given that azathioprine and mycophenolate mofetil inhibit purine metabolism, it is recommended that Myfortic not be administered concomitantly with azathioprine or <e2> mycophenolate mofetil </e2> .\n\n###\n\n", "completion": " false"}
{"id": 299, "relation": 1, "prompt": "Oral <e1> metronidazole </e1> has been reported to potentiate the anticoagulant effect of <e2> coumarin </e2> and warfarin, resulting in a prolongation of prothrombin time.\n\n###\n\n", "completion": " true"}
{"id": 39, "relation": 0, "prompt": "Azathioprine/Mycophenolate Mofetil: Given that <e1> azathioprine </e1> and mycophenolate mofetil inhibit purine metabolism, it is recommended that Myfortic not be administered concomitantly with azathioprine or <e2> mycophenolate mofetil </e2> .\n\n###\n\n", "completion": " false"}
{"id": 642, "relation": 1, "prompt": "Because of profound and long lasting inhibition of gastric acid secretion, <e1> pantoprazole </e1> may interfere with absorption of drugs where gastric pH is an important determinant of their bioavailability (eg, ketoconazole, ampicillin esters, and <e2> iron </e2> salts).\n\n###\n\n", "completion": " true"}
{"id": 42, "relation": 0, "prompt": "Azathioprine/Mycophenolate Mofetil: Given that azathioprine and <e1> mycophenolate mofetil </e1> inhibit purine metabolism, it is recommended that Myfortic not be administered concomitantly with azathioprine or <e2> mycophenolate mofetil </e2> .\n\n###\n\n", "completion": " false"}
{"id": 659, "relation": 1, "prompt": "<e1> Anticoagulants </e1> (such as heparin and vitamin K antagonists) and drugs that alter platelet function (such as acetylsalicylic acid, dipyridamole, and GP IIb/IIIa inhibitors) may increase the risk of bleeding if administered prior to, during, or after <e2> TNKase </e2> therapy.\n\n###\n\n", "completion": " true"}
{"id": 46, "relation": 0, "prompt": "<e1> Cholestyramine </e1> and Drugs that Bind Bile Acids: These drugs interrupt enterohepatic recirculation and reduce <e2> MPA </e2> exposure when coadministered with mycophenolate mofetil.\n\n###\n\n", "completion": " false"}
{"id": 670, "relation": 1, "prompt": "<e1> Aminoglutethimide </e1> administered concomitantly with <e2> depo-subQ provera 104 </e2> may significantly decrease the serum concentrations of MPA.\n\n###\n\n", "completion": " true"}
{"id": 47, "relation": 0, "prompt": "<e1> Cholestyramine </e1> and Drugs that Bind Bile Acids: These drugs interrupt enterohepatic recirculation and reduce MPA exposure when coadministered with <e2> mycophenolate mofetil </e2> .\n\n###\n\n", "completion": " false"}
{"id": 673, "relation": 1, "prompt": "<e1> Posicor </e1> inhibits some of the liver's ability to metabolize some other drugs - <e2> terfenadine </e2> , astemizole, cisapride, cyclosporine, and tricyclic antidepressants.\n\n###\n\n", "completion": " true"}
{"id": 60, "relation": 0, "prompt": "<e1> Live Vaccines </e1> : During treatment with <e2> Myfortic </e2> , the use of live attenuated vaccines should be avoided and patients should be advised that vaccinations may be less effective.\n\n###\n\n", "completion": " false"}
{"id": 676, "relation": 1, "prompt": "<e1> Posicor </e1> inhibits some of the liver's ability to metabolize some other drugs - terfenadine, astemizole, cisapride, <e2> cyclosporine </e2> , and tricyclic antidepressants.\n\n###\n\n", "completion": " true"}
{"id": 61, "relation": 0, "prompt": "<e1> Live Vaccines </e1> : During treatment with Myfortic, the use of <e2> live attenuated vaccines </e2> should be avoided and patients should be advised that vaccinations may be less effective.\n\n###\n\n", "completion": " false"}
{"id": 833, "relation": 1, "prompt": "Drugs that impair intestinal absorption of fat-soluble vitamins, such as <e1> cholestyramine </e1> , may interfere with the absorption of <e2> Zemplar </e2> Capsules.\n\n###\n\n", "completion": " true"}
{"id": 67, "relation": 0, "prompt": "Tetracycline, a bacteriostatic <e1> antibiotic </e1> , may antagonize the bactericidal effect of <e2> penicillin </e2> and concurrent use of these drugs should be avoided.\n\n###\n\n", "completion": " false"}
{"id": 885, "relation": 1, "prompt": "Cholestyramine: <e1> Cholestyramine </e1> causes a 60% reduction in the absorption and enterohepatic cycling of <e2> raloxifene </e2> and should not be coadministered with EVISTA.\n\n###\n\n", "completion": " true"}
{"id": 91, "relation": 0, "prompt": "Usage with <e1> Alcohol </e1> : Due to the potential for increased CNS depressants effects, <e2> alcohol </e2> should be used with caution in patients who are currently receiving pentazocine.\n\n###\n\n", "completion": " false"}
{"id": 924, "relation": 1, "prompt": "<e1> Sulfoxone </e1> may increase the effects of <e2> barbiturates </e2> , tolbutamide, and uricosurics.\n\n###\n\n", "completion": " true"}
{"id": 94, "relation": 0, "prompt": "<e1> Digoxin </e1> : There was a slight increase in the area under the curve (AUC, 11%) and mean peak drug concentration (Cmax, 18%) of <e2> digoxin </e2> with the co-administration of 100 mg sitagliptin for 10 days.\n\n###\n\n", "completion": " false"}
{"id": 992, "relation": 1, "prompt": "<e1> Paliperidone </e1> may antagonize the effect of levodopa and other <e2> dopamine agonists </e2> .\n\n###\n\n", "completion": " true"}
{"id": 103, "relation": 0, "prompt": "Although specific drug or food interactions with mifepristone have not been studied, on the basis of this drug s metabolism by CYP 3A4, it is possible that <e1> ketoconazole </e1> , itraconazole, <e2> erythromycin </e2> , and grapefruit juice may inhibit its metabolism (increasing serum levels of mifepristone).\n\n###\n\n", "completion": " false"}
{"id": 1065, "relation": 1, "prompt": "Vasopressors, particularly <e1> metaraminol </e1> , may cause serious cardiac arrhythmias during <e2> halothane </e2> anesthesia and therefore should be used only with great caution or not at all.\n\n###\n\n", "completion": " true"}
{"id": 110, "relation": 0, "prompt": "John s Wort, and certain <e1> anticonvulsants </e1> (phenytoin, <e2> phenobarbital </e2> , carbamazepine) may induce mifepristone metabolism (lowering serum levels of mifepristone).\n\n###\n\n", "completion": " false"}
{"id": 1072, "relation": 1, "prompt": "The pressor response of <e1> adrenergic agents </e1> may also be potentiated by <e2> tricyclic antidepressants </e2> .\n\n###\n\n", "completion": " true"}
{"id": 115, "relation": 0, "prompt": "John s Wort, and certain anticonvulsants ( <e1> phenytoin </e1> , phenobarbital, <e2> carbamazepine </e2> ) may induce mifepristone metabolism (lowering serum levels of mifepristone).\n\n###\n\n", "completion": " false"}
{"id": 1081, "relation": 1, "prompt": "Use with Other Central Nervous System Depressants: The depressant effects of <e1> morphine </e1> are potentiated by the presence of other CNS depressants such as alcohol, <e2> sedatives </e2> , antihistaminics, or psychotropic drugs.\n\n###\n\n", "completion": " true"}
{"id": 117, "relation": 0, "prompt": "John s Wort, and certain anticonvulsants ( <e1> phenytoin </e1> , phenobarbital, carbamazepine) may induce mifepristone metabolism (lowering serum levels of <e2> mifepristone </e2> ).\n\n###\n\n", "completion": " false"}
{"id": 1116, "relation": 1, "prompt": "The induction dose requirements of <e1> DIPRIVAN </e1> Injectable Emulsion may be reduced in patients with intramuscular or intravenous premedication, particularly with <e2> narcotics </e2> (eg, morphine, meperidine, and fentanyl, etc.)\n\n###\n\n", "completion": " true"}
{"id": 118, "relation": 0, "prompt": "John s Wort, and certain anticonvulsants (phenytoin, <e1> phenobarbital </e1> , <e2> carbamazepine </e2> ) may induce mifepristone metabolism (lowering serum levels of mifepristone).\n\n###\n\n", "completion": " false"}
{"id": 1424, "relation": 1, "prompt": "Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, <e1> Sanctura </e1> has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. <e2> digoxin </e2> , procainamide, pancuronium, morphine, vancomycin, metformin and tenofovir).\n\n###\n\n", "completion": " true"}
{"id": 122, "relation": 0, "prompt": "John s Wort, and certain anticonvulsants (phenytoin, phenobarbital, <e1> carbamazepine </e1> ) may induce mifepristone metabolism (lowering serum levels of <e2> mifepristone </e2> ).\n\n###\n\n", "completion": " false"}
{"id": 1427, "relation": 1, "prompt": "Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, <e1> Sanctura </e1> has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, <e2> morphine </e2> , vancomycin, metformin and tenofovir).\n\n###\n\n", "completion": " true"}
{"id": 129, "relation": 0, "prompt": "<e1> Vindesine </e1> can interact with the drugs of the following categories: - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity - Phenytoin: can increase seizure activity - <e2> Live virus vaccines </e2> : may potentiate the replication of the vaccine virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine - Mitomycin-C: may cause shortness of breath and bronchospasm - Killed virus vaccines: may decrease patient's response to the vaccine\n\n###\n\n", "completion": " false"}
{"id": 1428, "relation": 1, "prompt": "Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, <e1> Sanctura </e1> has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, <e2> vancomycin </e2> , metformin and tenofovir).\n\n###\n\n", "completion": " true"}
{"id": 132, "relation": 0, "prompt": "<e1> Vindesine </e1> can interact with the drugs of the following categories: - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity - Phenytoin: can increase seizure activity - Live virus vaccines: may potentiate the replication of the vaccine virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine - Mitomycin-C: may cause shortness of breath and bronchospasm - <e2> Killed virus vaccines </e2> : may decrease patient's response to the vaccine\n\n###\n\n", "completion": " false"}
{"id": 1715, "relation": 1, "prompt": "The neuromuscular blocking effect of <e1> MIVACRON </e1> may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral <e2> contraceptives </e2> , glucocorticoids, or certain monoamine oxidase inhibitors) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered phenytoin or carbamazepine.\n\n###\n\n", "completion": " true"}
{"id": 140, "relation": 0, "prompt": "Vindesine can interact with the drugs of the following categories: - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity - Phenytoin: can increase seizure activity - <e1> Live virus vaccines </e1> : may potentiate the replication of the vaccine virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine - <e2> Mitomycin-C </e2> : may cause shortness of breath and bronchospasm - Killed virus vaccines: may decrease patient's response to the vaccine\n\n###\n\n", "completion": " false"}
{"id": 1717, "relation": 1, "prompt": "The neuromuscular blocking effect of <e1> MIVACRON </e1> may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral contraceptives, glucocorticoids, or certain <e2> monoamine oxidase inhibitors </e2> ) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered phenytoin or carbamazepine.\n\n###\n\n", "completion": " true"}
{"id": 144, "relation": 0, "prompt": "Vindesine can interact with the drugs of the following categories: - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity - Phenytoin: can increase seizure activity - Live virus vaccines: may potentiate the replication of the <e1> vaccine </e1> virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine - Mitomycin-C: may cause shortness of breath and bronchospasm - <e2> Killed virus vaccines </e2> : may decrease patient's response to the vaccine\n\n###\n\n", "completion": " false"}
{"id": 1830, "relation": 1, "prompt": "Administration of <e1> valproic acid </e1> decreases oral clearance of <e2> temozolomide </e2> by about 5%.\n\n###\n\n", "completion": " true"}
{"id": 147, "relation": 0, "prompt": "Vindesine can interact with the drugs of the following categories: - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity - Phenytoin: can increase seizure activity - Live virus vaccines: may potentiate the replication of the vaccine virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine - <e1> Mitomycin-C </e1> : may cause shortness of breath and bronchospasm - Killed virus vaccines: may decrease patient's response to the <e2> vaccine </e2>\n\n###\n\n", "completion": " false"}
{"id": 1895, "relation": 1, "prompt": "<e1> Salicylates </e1> given concomitantly with <e2> anticoagulant drugs </e2> may predispose to systemic bleeding.\n\n###\n\n", "completion": " true"}
{"id": 163, "relation": 0, "prompt": "The following agents may increase certain actions or side effects of anticholinergic drugs: <e1> amantadine </e1> , <e2> antiarrhythmic agents of class I </e2> (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.\n\n###\n\n", "completion": " false"}
{"id": 1906, "relation": 1, "prompt": "<e1> Salicylate </e1> competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly <e2> corticosteroids </e2> .\n\n###\n\n", "completion": " true"}
{"id": 168, "relation": 0, "prompt": "The following agents may increase certain actions or side effects of anticholinergic drugs: <e1> amantadine </e1> , antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), <e2> benzodiazepines </e2> , MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.\n\n###\n\n", "completion": " false"}
{"id": 1954, "relation": 1, "prompt": "<e1> Triprolidine </e1> may enhance the sedative effects of central nervous system depressants including <e2> alcohol </e2> , barbiturates, hypnotics, narcotic analgesics, sedatives, and tranquillisers.\n\n###\n\n", "completion": " true"}
{"id": 169, "relation": 0, "prompt": "The following agents may increase certain actions or side effects of anticholinergic drugs: <e1> amantadine </e1> , antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, <e2> MAO inhibitors </e2> , narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.\n\n###\n\n", "completion": " false"}
{"id": 1958, "relation": 1, "prompt": "<e1> Triprolidine </e1> may enhance the sedative effects of central nervous system depressants including alcohol, barbiturates, hypnotics, narcotic analgesics, <e2> sedatives </e2> , and tranquillisers.\n\n###\n\n", "completion": " true"}
{"id": 171, "relation": 0, "prompt": "The following agents may increase certain actions or side effects of anticholinergic drugs: <e1> amantadine </e1> , antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., <e2> meperidine </e2> ), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.\n\n###\n\n", "completion": " false"}
{"id": 2007, "relation": 1, "prompt": "In clinical studies of TOBI, patients taking <e1> TOBI </e1> concomitantly with <e2> dornase alfa </e2> (PULMOZYME , Genentech), (beta)-agonists, inhaled corticosteroids, other anti-pseudomonal antibiotics, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole.\n\n###\n\n", "completion": " true"}
{"id": 176, "relation": 0, "prompt": "The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, <e1> antiarrhythmic agents of class I </e1> (e.g., <e2> quinidine </e2> ), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.\n\n###\n\n", "completion": " false"}
{"id": 2008, "relation": 1, "prompt": "In clinical studies of TOBI, patients taking <e1> TOBI </e1> concomitantly with dornase alfa ( <e2> PULMOZYME </e2> , Genentech), (beta)-agonists, inhaled corticosteroids, other anti-pseudomonal antibiotics, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole.\n\n###\n\n", "completion": " true"}
{"id": 182, "relation": 0, "prompt": "The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, <e1> antiarrhythmic agents of class I </e1> (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, <e2> narcotic analgesics </e2> (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.\n\n###\n\n", "completion": " false"}
{"id": 2041, "relation": 1, "prompt": "<e1> Phenothiazines </e1> are capable of potentiating <e2> CNS depressants </e2> (e.g., barbiturates, anesthetics, opiates, alcohol, etc.)\n\n###\n\n", "completion": " true"}
{"id": 192, "relation": 0, "prompt": "The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., <e1> quinidine </e1> ), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, <e2> MAO inhibitors </e2> , narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.\n\n###\n\n", "completion": " false"}
{"id": 2162, "relation": 1, "prompt": "one fatality has been reported from hypoglycemia in association with combined <e1> DIFLUCAN </e1> and <e2> glyburide </e2> use.\n\n###\n\n", "completion": " true"}
{"id": 196, "relation": 0, "prompt": "The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., <e1> quinidine </e1> ), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and <e2> nitrites </e2> , sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.\n\n###\n\n", "completion": " false"}
{"id": 2211, "relation": 1, "prompt": "Cisapride: There have been reports of cardiac events, including torsade de pointes in patients to whom <e1> fluconazole </e1> and <e2> cisapride </e2> were coadministered.\n\n###\n\n", "completion": " true"}
{"id": 200, "relation": 0, "prompt": "The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), <e1> antihistamines </e1> , antipsychotic agents (e.g., <e2> phenothiazines </e2> ), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.\n\n###\n\n", "completion": " false"}
{"id": 2225, "relation": 1, "prompt": "Tacrolimus: There have been reports of nephrotoxicity in patients to whom <e1> fluconazole </e1> and <e2> tacrolimus </e2> were coadministered.\n\n###\n\n", "completion": " true"}
{"id": 204, "relation": 0, "prompt": "The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), <e1> antihistamines </e1> , antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., <e2> meperidine </e2> ), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.\n\n###\n\n", "completion": " false"}
{"id": 2325, "relation": 1, "prompt": "Phenytoin, Carbamazepine, and Rifampicin: In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, <e1> carbamazepine </e1> , and rifampicin), the clearance of ondansetron was significantly increased and <e2> ondansetron </e2> blood concentrations were decreased.\n\n###\n\n", "completion": " true"}
{"id": 216, "relation": 0, "prompt": "The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, <e1> antipsychotic agents </e1> (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, <e2> sympathomimetic agents </e2> , tricyclic antidepressants, and other drugs having anticholinergic activity.\n\n###\n\n", "completion": " false"}
{"id": 2363, "relation": 1, "prompt": "Vasopressors, particularly <e1> metaraminol </e1> , may cause serious cardiac arrhythmias during <e2> halothane </e2> anesthesia and therefore should be used only with great caution or not at all.\n\n###\n\n", "completion": " true"}
{"id": 223, "relation": 0, "prompt": "The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., <e1> phenothiazines </e1> ), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and <e2> nitrites </e2> , sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.\n\n###\n\n", "completion": " false"}
{"id": 2399, "relation": 1, "prompt": "Based on an in vitro rat liver model, nitrogen substituted imidazole drugs (clotrimazole, ketoconazole, <e1> miconazole </e1> ) were potent, non-competitive inhibitors of <e2> trimetrexate </e2> metabolism.\n\n###\n\n", "completion": " true"}
